

The OncoAlert #ASCO21 Picks

Track: Early Breast Cancer

(Drs Erika Hamilton, Matteo Lambertini, Maryam Lustberg, Stephanie Graff, Icro Meattini, Kenin Punie)

OlympiA LBA1

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib

<https://bit.ly/2RELIJW>

501 BCI extended therapy

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

<https://bit.ly/3wtv8LT>

502 mammaprint extended therapy

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

<https://bit.ly/2QJALq6>

505 neoadjuvant talazoparib for BRCA mut

Neoadjuvant talazoparib in patients with germline *BRCA1/2* (g*BRCA1/2*) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

<https://bit.ly/34cbmbO>

503 ADAPT-HER-2 w/ survival

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

<https://bit.ly/349HJHU>

506 GeparNuevo and durva benefit

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

<https://bit.ly/3fewsMO>

605 ECOG-ACRIN EA1131

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

<https://bit.ly/3hOmm73>

516 PROMISE-GIM6 GnRH success during chemo for ov fxn preservation

Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.

<https://bit.ly/3wvbWxu>

Abstract 529

Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.

<https://bit.ly/3bRbNfX>

Abstract 500 MINDACT

Outcome of patients with an ultra low risk 70-gene signature in the MINDACT trial.

<https://bit.ly/3ufHq9k>